BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi Y, Lee S, Kim K, Kim SH, Chung YJ, Lee C. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med. 2018;50:99. [PMID: 30089794 DOI: 10.1038/s12276-018-0115-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2020;6:37-40. [DOI: 10.1016/j.euf.2019.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Odunsi A, McGray AJR, Miliotto A, Zhang Y, Wang J, Abiola A, Eppolito C, Huang RY. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies. J Immunother Cancer 2020;8:e001237. [PMID: 33177175 DOI: 10.1136/jitc-2020-001237] [Reference Citation Analysis]
3 Bray LJ, Hutmacher DW, Bock N. Addressing Patient Specificity in the Engineering of Tumor Models. Front Bioeng Biotechnol 2019;7:217. [PMID: 31572718 DOI: 10.3389/fbioe.2019.00217] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
4 Patel A, Cohen S, Moret R, Maresh G, Gobe GC, Li L. Patient-derived xenograft models to optimize kidney cancer therapies. Transl Androl Urol 2019;8:S156-65. [PMID: 31236333 DOI: 10.21037/tau.2018.11.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Khalil AS, Jaenisch R, Mooney DJ. Engineered tissues and strategies to overcome challenges in drug development. Adv Drug Deliv Rev 2020;158:116-39. [PMID: 32987094 DOI: 10.1016/j.addr.2020.09.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
6 Lohse S, Wasmer MS, Reydon TAC. Integrating Philosophy of Science into Research on Ethical, Legal and Social Issues in the Life Sciences. Perspectives on Science 2020;28:700-36. [DOI: 10.1162/posc_a_00357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Schlaak RA, SenthilKumar G, Boerma M, Bergom C. Advances in Preclinical Research Models of Radiation-Induced Cardiac Toxicity. Cancers (Basel) 2020;12:E415. [PMID: 32053873 DOI: 10.3390/cancers12020415] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
8 Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel) 2021;13:440. [PMID: 33503832 DOI: 10.3390/cancers13030440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Park I, Hong S, Seok J, Lucia SE, Song E, Kim M, Kong E, Seo H, Hwang Y, Ahn S, Kim S, Jang DH, Lee JH, Park SH, Kim P, Jo YH. Longitudinal Intravital Imaging of Tumor-Infiltrating Lymphocyte Motility in Breast Cancer Models. J Breast Cancer 2021;24:463-73. [PMID: 34652077 DOI: 10.4048/jbc.2021.24.e40] [Reference Citation Analysis]
10 Baschnagel AM, Kaushik S, Durmaz A, Goldstein S, Ong IM, Abel L, Clark PA, Gurel Z, Leal T, Buehler D, Iyer G, Scott JG, Kimple RJ. Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Sci Rep 2021;11:2520. [PMID: 33510214 DOI: 10.1038/s41598-021-81832-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Schmitt M, Sinnberg T, Niessner H, Forschner A, Garbe C, Macek B, Nalpas NC. Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. Cancers (Basel) 2021;13:5411. [PMID: 34771574 DOI: 10.3390/cancers13215411] [Reference Citation Analysis]
12 Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: Past, present and future perspectives. World J Gastroenterol 2020; 26(13): 1394-1426 [PMID: 32308343 DOI: 10.3748/wjg.v26.i13.1394] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 34] [Article Influence: 21.0] [Reference Citation Analysis]
13 Abreu TR, Biscaia M, Gonçalves N, Fonseca NA, Moreira JN. In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. Adv Exp Med Biol 2021;1295:271-99. [PMID: 33543464 DOI: 10.1007/978-3-030-58174-9_12] [Reference Citation Analysis]
14 Sobczuk P, Brodziak A, Khan MI, Chhabra S, Fiedorowicz M, Wełniak-Kamińska M, Synoradzki K, Bartnik E, Cudnoch-Jędrzejewska A, Czarnecka AM. Choosing The Right Animal Model for Renal Cancer Research. Transl Oncol 2020;13:100745. [PMID: 32092671 DOI: 10.1016/j.tranon.2020.100745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Nikolakopoulou P, Rauti R, Voulgaris D, Shlomy I, Maoz BM, Herland A. Recent progress in translational engineered in vitro models of the central nervous system. Brain 2020;143:3181-213. [PMID: 33020798 DOI: 10.1093/brain/awaa268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
16 Raimondi G, Mato-Berciano A, Pascual-Sabater S, Rovira-Rigau M, Cuatrecasas M, Fondevila C, Sánchez-Cabús S, Begthel H, Boj SF, Clevers H, Fillat C. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine 2020;56:102786. [PMID: 32460166 DOI: 10.1016/j.ebiom.2020.102786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Testa U, Castelli G, Pelosi E. Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med Sci (Basel) 2020;8:E18. [PMID: 32210163 DOI: 10.3390/medsci8010018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
18 Arranz L. The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies. Cancers (Basel) 2022;14:580. [PMID: 35158848 DOI: 10.3390/cancers14030580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hicks WH, Bird CE, Traylor JI, Shi DD, El Ahmadieh TY, Richardson TE, McBrayer SK, Abdullah KG. Contemporary Mouse Models in Glioma Research. Cells 2021;10:712. [PMID: 33806933 DOI: 10.3390/cells10030712] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 de Souza JC, Miguita L, Gomez RS, Gomes CC. Patient-derived xenograft models for the study of benign human neoplasms. Exp Mol Pathol 2021;120:104630. [PMID: 33744281 DOI: 10.1016/j.yexmp.2021.104630] [Reference Citation Analysis]
21 Wang J, Fang X, Zhang C, Ji H, Pang Q, Li X, Luo Z, Wu Q, Zhang L. Development of Aptamer-Based Molecular Tools for Rapid Intraoperative Diagnosis and In Vivo Imaging of Serous Ovarian Cancer. ACS Appl Mater Interfaces 2021;13:16118-26. [PMID: 33787226 DOI: 10.1021/acsami.1c02072] [Reference Citation Analysis]
22 Shingleton J, Wang J, Baloh C, Dave T, Davis N, Happ L, Jadi O, Kositsky R, Li X, Love C, Panea R, Qin Q, Reddy A, Singhi N, Smith E, Thakkar D, Dave SS. Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells. Cold Spring Harb Perspect Med 2021;11:a034843. [PMID: 32152246 DOI: 10.1101/cshperspect.a034843] [Reference Citation Analysis]
23 Marayati R, Bownes LV, Stafman LL, Williams AP, Quinn CH, Atigadda V, Aye JM, Stewart JE, Yoon KJ, Beierle EA. 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts. Transl Oncol 2021;14:100893. [PMID: 33010553 DOI: 10.1016/j.tranon.2020.100893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Durinikova E, Buzo K, Arena S. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. J Exp Clin Cancer Res 2021;40:185. [PMID: 34090508 DOI: 10.1186/s13046-021-01981-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Want MY, Konstorum A, Huang RY, Jain V, Matsueda S, Tsuji T, Lugade A, Odunsi K, Koya R, Battaglia S. Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer. Oncoimmunology 2019;8:e1586042. [PMID: 31069153 DOI: 10.1080/2162402X.2019.1586042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
26 Pistollato F, Bernasconi C, McCarthy J, Campia I, Desaintes C, Wittwehr C, Deceuninck P, Whelan M. Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research. Animals (Basel) 2020;10:E1194. [PMID: 32674379 DOI: 10.3390/ani10071194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Lee NP, Chan CM, Tung LN, Wang HK, Law S. Tumor xenograft animal models for esophageal squamous cell carcinoma. J Biomed Sci 2018;25:66. [PMID: 30157855 DOI: 10.1186/s12929-018-0468-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
28 Palacios-Acedo AL, Mege D, Crescence L, Panicot-Dubois L, Dubois C. Cancer animal models in thrombosis research. Thromb Res 2020;191 Suppl 1:S112-6. [PMID: 32736767 DOI: 10.1016/S0049-3848(20)30407-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hong HK, Yun NH, Jeong YL, Park J, Doh J, Lee WY, Cho YB. Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling. Cancer Med 2021;10:5589-98. [PMID: 34240815 DOI: 10.1002/cam4.4114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Seastedt KP, Pruett N, Hoang CD. Mouse models for mesothelioma drug discovery and development. Expert Opin Drug Discov 2021;16:697-708. [PMID: 33380218 DOI: 10.1080/17460441.2021.1867530] [Reference Citation Analysis]
31 da Cunha AA, Silveira JS, Antunes GL, Abreu da Silveira K, Benedetti Gassen R, Vaz Breda R, Márcio Pitrez P. Cysteinyl leukotriene induces eosinophil extracellular trap formation via cysteinyl leukotriene 1 receptor in a murine model of asthma. Exp Lung Res 2021;47:355-67. [PMID: 34468256 DOI: 10.1080/01902148.2021.1923864] [Reference Citation Analysis]
32 Trusler O, Goodwin J, Laslett AL. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochim Biophys Acta Rev Cancer 2021;1875:188459. [PMID: 33129865 DOI: 10.1016/j.bbcan.2020.188459] [Reference Citation Analysis]
33 Marayati R, Bownes LV, Quinn CH, Wadhwani N, Williams AP, Markert HR, Atigadda V, Aye JM, Stewart JE, Yoon KJ, Beierle EA. Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts. J Pediatr Surg 2021;56:1165-73. [PMID: 33762121 DOI: 10.1016/j.jpedsurg.2021.02.041] [Reference Citation Analysis]
34 Maulana TI, Kromidas E, Wallstabe L, Cipriano M, Alb M, Zaupa C, Hudecek M, Fogal B, Loskill P. Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Adv Drug Deliv Rev 2021;173:281-305. [PMID: 33798643 DOI: 10.1016/j.addr.2021.03.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
35 Torres-Ayuso P, Brognard J. Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers (Basel) 2019;11:E1972. [PMID: 31817861 DOI: 10.3390/cancers11121972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Cardenas JJ, Robles-Oteiza C, Politi K. Assessment of IFNγ responsiveness in patient-derived xenografts. Methods Enzymol 2020;631:415-27. [PMID: 31948560 DOI: 10.1016/bs.mie.2019.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Mendes N, Dias Carvalho P, Martins F, Mendonça S, Malheiro AR, Ribeiro A, Carvalho J, Velho S. Animal Models to Study Cancer and Its Microenvironment. Adv Exp Med Biol 2020;1219:389-401. [PMID: 32130710 DOI: 10.1007/978-3-030-34025-4_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Hua J, Wu P, Gan L, Zhang Z, He J, Zhong L, Zhao Y, Huang Y. Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy. Front Oncol 2021;11:738323. [PMID: 34868932 DOI: 10.3389/fonc.2021.738323] [Reference Citation Analysis]
39 Dhandapani H, Seetharaman A, Jayakumar H, Ganeshrajah S, Singh SS, Thangarajan R, Ramanathan P. Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro. J Gynecol Oncol 2021;32:e59. [PMID: 33908712 DOI: 10.3802/jgo.2021.32.e59] [Reference Citation Analysis]
40 Saddawi-Konefka R, Simon AB, Sumner W, Sharabi A, Mell LK, Cohen EEW. Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Front Oncol 2021;11:738626. [PMID: 34621678 DOI: 10.3389/fonc.2021.738626] [Reference Citation Analysis]
41 Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, Current, and Future of Immunotherapies for Prostate Cancer.Front Oncol. 2019;9:884. [PMID: 31572678 DOI: 10.3389/fonc.2019.00884] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
42 Pusuluri A, Wu D, Mitragotri S. Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. Journal of Controlled Release 2019;305:130-54. [DOI: 10.1016/j.jconrel.2019.04.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
43 Lohse S. Scientific inertia in animal-based research in biomedicine. Stud Hist Philos Sci 2021;89:41-51. [PMID: 34333156 DOI: 10.1016/j.shpsa.2021.06.016] [Reference Citation Analysis]
44 Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol 2021;12:607282. [PMID: 33854497 DOI: 10.3389/fimmu.2021.607282] [Reference Citation Analysis]
45 Jin F, Jin-lee HJ, Johnson AJ. Mouse Models of Experimental Glioblastoma. In: Debinski W, editor. Gliomas. Exon Publications; 2021. pp. 15-46. [DOI: 10.36255/exonpublications.gliomas.2021.chapter2] [Reference Citation Analysis]
46 Karakashev S, Zhang RG. Mouse models of epithelial ovarian cancer for preclinical studies. Zool Res 2021;42:153-60. [PMID: 33527800 DOI: 10.24272/j.issn.2095-8137.2020.382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Terlizzi C, De Rosa V, Iommelli F, Altobelli GG, Fonti R, Del Vecchio S. Preclinical imaging for targeting cancer immune evasion. Q J Nucl Med Mol Imaging 2020;64. [DOI: 10.23736/s1824-4785.20.03254-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Horak V, Palanova A, Cizkova J, Miltrova V, Vodicka P, Kupcova Skalnikova H. Melanoma-Bearing Libechov Minipig (MeLiM): The Unique Swine Model of Hereditary Metastatic Melanoma. Genes (Basel) 2019;10:E915. [PMID: 31717496 DOI: 10.3390/genes10110915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
49 Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol 2020;72:239-49. [PMID: 31954489 DOI: 10.1016/j.jhep.2019.09.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
50 Di Blasio S, van Wigcheren GF, Becker A, van Duffelen A, Gorris M, Verrijp K, Stefanini I, Bakker GJ, Bloemendal M, Halilovic A, Vasaturo A, Bakdash G, Hato SV, de Wilt JHW, Schalkwijk J, de Vries IJM, Textor JC, van den Bogaard EH, Tazzari M, Figdor CG. The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nat Commun 2020;11:2749. [PMID: 32488012 DOI: 10.1038/s41467-020-16583-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
51 Olgasi C, Cucci A, Follenzi A. iPSC-Derived Liver Organoids: A Journey from Drug Screening, to Disease Modeling, Arriving to Regenerative Medicine. Int J Mol Sci 2020;21:E6215. [PMID: 32867371 DOI: 10.3390/ijms21176215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
52 Okada S, Vaeteewoottacharn K, Kariya R. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 2019;8:E889. [PMID: 31412684 DOI: 10.3390/cells8080889] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]
53 Teijeira Crespo A, Burnell S, Capitani L, Bayliss R, Moses E, Mason GH, Davies JA, Godkin AJ, Gallimore AM, Parker AL. Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 2021;163:389-98. [PMID: 33638871 DOI: 10.1111/imm.13323] [Reference Citation Analysis]
54 Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res 2021;40:178. [PMID: 34074330 DOI: 10.1186/s13046-021-01970-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Iglesias-Carres L, Neilson AP. Utilizing preclinical models of genetic diversity to improve translation of phytochemical activities from rodents to humans and inform personalized nutrition. Food Funct 2021;12:11077-105. [PMID: 34672309 DOI: 10.1039/d1fo02782d] [Reference Citation Analysis]
56 Janke LJ, Imai DM, Tillman H, Doty R, Hoenerhoff MJ, Xu JJ, Freeman ZT, Allen P, Fowlkes NW, Iacobucci I, Dickerson K, Mullighan CG, Vogel P, Rehg JE. Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts. Vet Pathol 2021;58:181-204. [PMID: 33208054 DOI: 10.1177/0300985820970144] [Reference Citation Analysis]
57 Hofving T, Liang F, Karlsson J, Yrlid U, Nilsson JA, Nilsson O, Nilsson LM. The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. Cancers (Basel) 2021;13:4305. [PMID: 34503115 DOI: 10.3390/cancers13174305] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Onaciu A, Munteanu R, Munteanu VC, Gulei D, Raduly L, Feder RI, Pirlog R, Atanasov AG, Korban SS, Irimie A, Berindan-Neagoe I. Spontaneous and Induced Animal Models for Cancer Research. Diagnostics (Basel) 2020;10:E660. [PMID: 32878340 DOI: 10.3390/diagnostics10090660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
59 Carpenter R, Oh HJ, Ham IH, Kim D, Hur H, Lee J. Scaffold-Assisted Ectopic Transplantation of Internal Organs and Patient-Derived Tumors. ACS Biomater Sci Eng 2019;5:6667-78. [PMID: 33423485 DOI: 10.1021/acsbiomaterials.9b00978] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]